Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad. Reisinger KS, et al. Among authors: silas pe. Pediatrics. 2006 Feb;117(2):265-72. doi: 10.1542/peds.2005-0092. Pediatrics. 2006. PMID: 16452343 Clinical Trial.
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301–Pediatric Expansion Study Group. Áñez G, et al. JAMA Netw Open. 2023 Apr 3;6(4):e239135. doi: 10.1001/jamanetworkopen.2023.9135. JAMA Netw Open. 2023. PMID: 37099299 Free PMC article. Clinical Trial.
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, Silas PE, Sarpong KO, Ramsey KP, Fling JA, Speicher D, Campos M, Munjal I, Peltier C, Vesikari T, Baccarini C, Caplanusi A, Gillard P, Carryn S, Henry O. Klein NP, et al. Among authors: silas pe. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):194-201. doi: 10.1093/jpids/piz010. J Pediatric Infect Dis Soc. 2020. PMID: 30849175 Free PMC article. Clinical Trial.
Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: Results from a phase 3, randomized trial.
Abu-Elyazeed R, Klein NP, Moerman L, Povey M, Pruitt A, Senders S, Silas P, Bi D; Rota-090 Study Group. Abu-Elyazeed R, et al. Vaccine. 2021 Mar 5;39(10):1534-1543. doi: 10.1016/j.vaccine.2020.08.070. Epub 2020 Oct 17. Vaccine. 2021. PMID: 33077301 Free article. Clinical Trial.
A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).
Silas PE, Zissman EN, Gardner J, Helian S, Lee AW, Platt HL. Silas PE, et al. Hum Vaccin Immunother. 2020 Nov 1;16(11):2634-2640. doi: 10.1080/21645515.2020.1743122. Epub 2020 May 19. Hum Vaccin Immunother. 2020. PMID: 32429738 Free PMC article. Clinical Trial.
A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age.
Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. Pavia-Ruz N, et al. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19. Hum Vaccin Immunother. 2013. PMID: 23782962 Free PMC article. Clinical Trial.
Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S. Klein NP, et al. Among authors: silas pe. Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20. Vaccine. 2017. PMID: 28536030 Free article. Clinical Trial.
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM. Abdelnour A, et al. Among authors: silas pe. Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4. Vaccine. 2014. PMID: 24397906 Clinical Trial.
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Griffin MP, et al. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. N Engl J Med. 2020. PMID: 32726528 Clinical Trial.
16 results